Literature DB >> 6638038

Short- and long-term (six-year) hemodynamic effects of labetalol in essential hypertension.

P Lund-Johansen.   

Abstract

The acute blood pressure lowering effect of intravenous labetalol (0.2 to 0.8 mg/kg) was studied in 11 patients with severe hypertension. The blood pressure was reduced by 22 percent partly due to a decrease in total peripheral resistance (-14 percent) and partly due to a reduction in cardiac output (-10 percent). Stroke volume was unchanged. Fifteen patients with moderate essential hypertension were studied at rest and during exercise before and after one and six years of labetalol therapy. Blood pressure was reduced approximately 22 percent at rest as well as during exercise, mainly due to a reduction in total peripheral resistance. However, after one year, cardiac index was reduced 10 to 14 percent (p less than 0.01) at rest (sitting) and during exercise due to a reduction in heart rate not compensated for by an increase in stroke volume. During the next five years, blood pressure control was maintained, but cardiac index tended to increase and was not significantly reduced in any situation six years after treatment was started. Total peripheral resistance decreased significantly and was reduced 15 to 20 percent (p less than 0.01) after six years. Stroke index increased about 10 to 15 percent (p less than 0.01). These alterations are the opposite of what is seen in untreated hypertensive patients restudied after 10 and 17 years. The normalization of central hemodynamics could reflect the regression of structural changes in the heart and in the resistance vessels.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6638038     DOI: 10.1016/0002-9343(83)90133-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  10 in total

Review 1.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

Review 2.  Systemic and regional haemodynamic profile of diuretics and alpha- and beta-blockers. A review comparing acute and chronic effects.

Authors:  A Mimran; G Ducailar
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 3.  Acute and chronic hemodynamic effects of drugs with different actions on adrenergic receptors: a comparison between alpha blockers and different types of beta blockers with and without vasodilating effect.

Authors:  P Lund-Johansen; P Omvik
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

Review 4.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.

Authors:  R Donnelly; G J Macphee
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

Review 6.  Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.

Authors:  P Lund-Johansen
Journal:  Drugs       Date:  1984       Impact factor: 9.546

Review 7.  Role of vasodilation in the antihypertensive and antianginal effects of labetalol: implications for therapy of combined hypertension and angina.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

Review 8.  Management of hypertension in actively exercising patients. Implications for drug selection.

Authors:  D Klaus
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

Review 9.  The role of multiple action agents in hypertension.

Authors:  P Lund-Johansen; P Omvik
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

10.  Choosing initial antihypertensive drug therapy for the uncomplicated hypertensive patient.

Authors:  M A Moore
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Jan-Feb       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.